PFE - Pfizer Inc. (NYSE:PFE)

quorthon

Nuovo Utente
Registrato
9/11/07
Messaggi
2.265
Punti reazioni
100
ci stavo facendo un pensierino anche io,il prezzo mi sembra ottimo
 

adolar

MEMBER
Registrato
9/6/00
Messaggi
49.069
Punti reazioni
1.635
tua moglie non ti ha insegnato che forse è meglio dire anche quando esci e non solo quando entri?

:D

hai ragione, non ci avevo pensato:D:D:D
Ma ho detto che non mi hanno fatto uscire perchè i toscani si sono fatti la pasquetta:rolleyes:
 

adolar

MEMBER
Registrato
9/6/00
Messaggi
49.069
Punti reazioni
1.635
Pfizer: Eps pro-forma oltre le attese a 0,54 $ nel I trim., tagliate le stime 2009

Finanzaonline.com - 28.4.09/13:32

Profitti in lieve calo per Pfizer nel primo trimestre 2009. Il gruppo farmaceutico statunitense ha riportato un utile netto di 2,73 miliardi di dollari, pari a 0,40 dollari ad azione, dai 2,78 miliardi dell'analogo trimestre 2008. L'Eps al netto delle poste straordinarie risulta di 0,54 dollari, sopra le attese che erano di 0,49 dollari. Tagliate le stime di Eps per l'intero 2009 che sono passate a un range di 1,20-1,35 dollari dall'1,34-1,49 precedentemente stimato. Confermato invece il target di fatturato a tra 44 ed i 46 miliardi di dollari.
 

adolar

MEMBER
Registrato
9/6/00
Messaggi
49.069
Punti reazioni
1.635
massima attenzione su questo titolo, perchè è in atto un arbitraggio con Wyeth che prevede per ogni azione di questa, il pagamento di 33$ + lo 0,985 di una azione PFE

01 / 26 / 2009


Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company
Diversification, Flexibility and Scale Position New Company for Success in Dynamic Global Health Care Environment

Establishes Leadership in Human, Animal, and Consumer Health, including Primary and Specialty Care; in Vaccines, Biologics and Small Molecules; and Across Developed and Emerging Markets

Unique and Flexible Business Model Features Focus and Agility of Smaller Enterprises Backed by Resources and Scale of Global Company

Combination Strengthens Platform for Improved, Consistent, and Stable Earnings Growth and Sustainable Shareholder Value

New Company Will Promote Health and Wellness and Respond More Effectively to Unmet Needs of Patients, Physicians, and Customers Around the World


NEW YORK, NY and MADISON, NJ--January 26, 2009 – Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The Boards of Directors of both companies have approved the combination.

The combined company will create one of the most diversified companies in the global health care industry. Operating through patient-centric businesses that match the speed and agility of small, focused enterprises with the benefits of a global organization’s scale and resources, the company will respond more quickly and effectively to meet changing health care needs. The combined company will have product offerings in numerous growing therapeutic areas, a strong product pipeline, leading scientific and manufacturing capabilities, and a premier global footprint in health care.

With its broad and diversified global product portfolio and reduced dependence on small molecules, the new company will be positioned for improved, consistent, and stable top-line and EPS growth and sustainable shareholder value in the short and long term. It is expected that no drug will account for more than 10 percent of the combined company’s revenue in 2012.

Financial Highlights

Under the terms of the transaction, each outstanding share of Wyeth common stock will be converted into the right to receive $33 in cash and 0.985 of a share of Pfizer common stock, subject to the terms of the merger agreement. Based on the closing price of Pfizer stock as of January 23, 2009, the stock component is valued at $17.19 per share. The transaction provides immediate value to Wyeth shareholders through the cash component, as well as continued participation in the future prospects expected to result from the combination through their ownership of approximately 16 percent of Pfizer’s shares.

The deal is expected to be accretive to Pfizer’s adjusted diluted earnings per share in the second full year after closing(1). The transaction is anticipated to yield cost savings of approximately $4 billion to be fully realized by the third year after closing. Savings are expected in selling, informational and administrative functions, research and development, and manufacturing.

The transaction will be financed through a combination of cash, debt and stock. A consortium of banks has provided commitments for a total of $22.5 billion in debt.

In connection with the proposed transaction between Pfizer and Wyeth, the Board of Directors of Pfizer has determined that, effective with the dividend to be paid in the second quarter of 2009, it will reduce Pfizer’s quarterly dividend per share to $0.16, which continues to be competitive with other industry participants. Pfizer believes the transaction offers significant opportunities to enhance long-term shareholder value.

Strategic Overview

Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer, said: “The combination of Pfizer and Wyeth provides a powerful opportunity to transform our industry. It will produce the world’s premier biopharmaceutical company whose distinct blend of diversification, flexibility, and scale positions it for success in a dynamic global health care environment. The new company will be an industry leader in human, animal and consumer health. With our combined biopharmaceuticals business, it will lead in primary and specialty care as well as in small and large molecules. Its geographic presence in most of the world’s developed and developing countries will be unrivaled.”

Bernard Poussot, Chairman, President and Chief Executive Officer of Wyeth, said, “Wyeth’s commitment to scientific innovation has enabled us to build a diversified biopharmaceutical company with leadership in attractive growth areas such as vaccines, nutritionals and biologics. For example, Wyeth developed Prevnar, the first pneumococcal vaccine for infants. In addition, because we were early to see the potential of biotechnology to create life-changing medicines, we now have a strong franchise which includes Enbrel, the number one biotechnology product in the world. With our business focused on prevention and wellness, Wyeth is well positioned in today’s rapidly changing health care environment. Our employees should be enormously proud of what we have built and confident that combining with Pfizer will accelerate our pursuit of innovative new medicines to meet critical unmet patient needs. Wyeth and Pfizer are highly complementary businesses, and together we can build the best diversified health care company in the world. We believe we can better execute our strategy and can accomplish far more together in the years ahead than either company could have achieved on its own.”

Mr. Kindler continued, “With this combination, Pfizer will offer patients around the world a uniquely broad and diversified portfolio of biopharmaceutical innovations through business units--each one focused on different customer needs and backed by the resources of a premier global organization. By combining the spirit of small, agile enterprises with our combined scale, Pfizer will advance its mission of working together toward a healthier world.”

Over the last two years, Pfizer has become a leaner, more disciplined, and far stronger company that is now capable of – and has demonstrated – superior and consistent execution of its strategies and commitments. As separately announced today, for example, Pfizer achieved its 2008 objectives despite the challenging economy, including meeting or exceeding its financial guidance and cost-reduction target.

With this essential foundation established, the combination with Wyeth meaningfully advances in a single transaction each of the strategic priorities that Pfizer has identified and pursued over the last two years, including:
• Enhancing the in-line and pipeline patent-protected portfolio in key “Invest to Win” disease areas, such as Alzheimer’s disease, inflammation, oncology, pain and psychosis;
• Becoming a top-tier player in biotherapeutics and vaccines;
• Accelerating growth in emerging markets;
• Creating new opportunities for established products;
• Investing in complementary businesses; and
• Creating a lower, more flexible cost base.

Mr. Kindler added, “Over the last several years, Wyeth’s leadership and its employees have done an outstanding job creating a strong, diversified biopharmaceutical company. The people, products, and technologies that Wyeth brings to the new company will enhance our scientific capabilities and drive further commercial innovation to improve the health of the patients we serve. The compelling combination of Pfizer and Wyeth allows us to advance our newly strengthened organization to the next level by harnessing the talents of the best people from both companies. This will enable us to accelerate significantly our progress along ‘Our Path Forward’ as we pursue our mission of applying innovative science to improve world health.”

Global Biopharmaceutical Leadership and Business Diversification

The combination of Pfizer and Wyeth will create the world’s premier biopharmaceutical company with a broad range of therapeutic solutions for many health challenges and preventive care.

For Patients Today – A Broad Portfolio of Health Care Solutions and Treatments

The combined company will offer customers and patients a broad range of products for every stage of life--with top tier portfolios in key therapeutic areas such as cardiovascular, oncology, women’s health, central nervous system, and infectious disease and a diverse product portfolio that includes 17 products with more than $1 billion each in annual revenue. Pfizer will be the second largest specialty care provider, with products including the world’s leading biologic, Enbrel; Prevnar, the world’s largest-selling vaccine; Sutent for cancer; Geodon for schizophrenia; and Zyvox for infection. The transaction also builds upon Pfizer’s position as a global leader in animal health, with strong product lines in attractive segments, for companion animals, biologics and anti-infectives.

For Patients Tomorrow – A Diverse Range of Technology and Research Platforms

The new company will have more resources to invest in research and development than any other biopharmaceutical company and access to all leading scientific technology platforms, including vaccines, small and large molecules, nutritionals and consumer products.

The combination also brings together a robust pipeline of biopharmaceutical research and development projects, including programs in diabetes, inflammation/immunology, oncology and pain, as well as significant opportunities in Wyeth’s Alzheimer’s disease pipeline, which has a number of compounds in development, including phase three biotech compound Bapineuzumab. These will be added to the exciting agents currently in early and later stage development at Pfizer for Alzheimer’s disease, illustrating the breadth and depth the new company will be able to use in targeting the diseases that most affect patients.

The new company will have an enhanced ability to innovate, operating as focused business units tailored to patients and other customers. Each business unit will oversee product development from clinical trials to commercialization. This approach will allow for rapid decision-making and a more efficient use of resources and, as a result, will enhance the company’s ability to invest in long-term opportunities. The combination will also provide additional high quality and high volume manufacturing capabilities, including Wyeth’s Grange Castle, Ireland facility, the largest integrated biotechnology manufacturing facility in the world.

For Patients Everywhere – A Strong Global Presence

Geographically, the combination will enhance Pfizer’s and Wyeth’s compelling portfolios in important growth areas. Based on IMS data, the combined company will be number one in terms of biopharmaceutical revenues in the United States with an approximately 12% market share; in Europe with an approximately 10% share; in Asia (ex-Japan) with an approximately 7% share; in Japan with a 6% share; and in Latin America with a 6% share.

Pfizer and Wyeth’s combined presence will be significant in high-growth emerging markets, such as Latin America, the Middle East and China, where Wyeth has an impressive presence in infant nutritionals and Pfizer is a recognized leader in pharmaceuticals. This enhanced geographic position will further strengthen the combined company’s business, provide increased exposure to high-growth, less-developed and under-penetrated markets, and provide compelling opportunities for expense savings.

Conditions

The proposed transaction is subject to customary closing conditions, including approval by the stockholders of Wyeth, notification and clearance under certain antitrust statutes. In addition, the proposed transaction is subject to Pfizer’s financing sources not declining to provide the financing due to a material adverse change with respect to Pfizer or Pfizer failing to maintain credit ratings of A2/A long-term stable/stable and A1/P1 short term affirmed. There are no other financing conditions to closing in the merger agreement. Pfizer and Wyeth expect the transaction to close at the end of the third quarter or during the fourth quarter 2009.

Advisors

Pfizer’s lead financial advisors are Bank of America Merrill Lynch, Goldman Sachs and J.P. Morgan. Barclays and Citigroup are acting as financial advisors. Its legal advisor is Cadwalader, Wickersham & Taft LLP. Wyeth’s financial advisors are Morgan Stanley and Evercore Partners and its legal advisor is Simpson Thacher & Bartlett LLP. In addition, Wachtell, Lipton, Rosen & Katz served as counsel to Wyeth’s Board of Directors.

Conference Call/Webcast

Pfizer and Wyeth will be conducting an analyst and investor conference call/webcast Monday January 26, 2009 at 8:30am to discuss its proposed combination. The webcast can be accessed on the investor relations sections of the two companies’ websites, www.pfizer.com and www.wyeth.com. You can also listen to the conference call by dialing either (866) 331-6338 in the United States or (347) 284-6938 outside of the United States. The password is “Pfizer”.

Press Conference

Pfizer and Wyeth will be holding a press conference with senior executives from both companies Monday, January 26, 2009 at 10:00am at Pfizer’s corporate headquarters located at 235 East 42nd Street, N.Y., N.Y.

Video Interview with CEOs Jeff Kindler and Bernard Poussot

A video interview with Jeff Kindler and Bernard Poussot is available for viewing at www.premierbiopharma.com, a website set up for information about the combination.

For Broadcast Media

Broadcast media may download a broadcast-quality version of the video interview at http://w3.cantos.com/09/pfizer_wyeth/. This link is not for viewing but exclusively designed for broadcast download.
 

asqueldaz

Nuovo Utente
Sospeso dallo Staff
Registrato
19/2/08
Messaggi
20.659
Punti reazioni
255
Tuesday, 20 October 2009 06:22


Analysts were expecting Pfizer Inc. (PFE) [Chart - News - Analysis] to report earnings of $0.48 for last quarter, but PFE beat expectations with actual earnings of $0.51---3 cents above the consensus estimate. PFE also issued earnings guidance for next quarter that is above current analyst expectations.


http://www.learningmarkets.com/inde...c-beats-analyst-expectations-pfe-jnj-nvs.html
 

Toniopuca

Nuovo Utente
Registrato
22/8/11
Messaggi
4
Punti reazioni
0
Pfizer

Ciao a tutti sono nuovo del forum e volevo un vostro parere...che ne dite del titolo Pfizer?
Lo si compra con un buono sconto visto la discesa recente del NYSE, l'azienda è solida, il business è quello farmaceutico (sostanzialmente solido) e poi si è ripresa bene dalla discesa del 2010
 

Seven Of Nine

Risk/Reward
Registrato
12/6/07
Messaggi
8.249
Punti reazioni
441
L'ultima trimestrale mi ha convinto OK!
In passato sono stato molto critico verso la società ma il cambio di CEO le ha fatto bene e credo che adesso sia sulla giusta strada. :yes:

Sta perdendo in questo periodo l'esclusività del Lipitor ma la situazione mi sembra ora prezzata nel mercato quindi ormai è storia vecchia. L'ho inserita come choice pharma nell'SI4 pronto per un nuova competizione contro l'S&P 500.
http://www.finanzaonline.com/forum/analisi-fondamentale/1359925-son-index-4-armageddon.html :yes:
 

shark2007

The Little Ice Age
Registrato
27/10/07
Messaggi
52.531
Punti reazioni
1.133
L'ultima trimestrale mi ha convinto OK!
In passato sono stato molto critico verso la società ma il cambio di CEO le ha fatto bene e credo che adesso sia sulla giusta strada. :yes:

Sta perdendo in questo periodo l'esclusività del Lipitor ma la situazione mi sembra ora prezzata nel mercato quindi ormai è storia vecchia. L'ho inserita come choice pharma nell'SI4 pronto per un nuova competizione contro l'S&P 500.
http://www.finanzaonline.com/forum/analisi-fondamentale/1359925-son-index-4-armageddon.html :yes:

Io invece avevo iniziato ad inserire Pfizer nel mio portafoglio titoli (portafoglio reale, non simulato ...! :yes:) quando le quotazioni erano cedenti attorno a 13 USD ... ed il cambio eur/usd era attorno a 1,40-1,45 ... :cool:

E fra qualche settimana potrei cominciare ad alleggerire la posizione approfittando delle quotazioni in ascesa continua ... OK!
 
Ultima modifica:

asqueldaz

Nuovo Utente
Sospeso dallo Staff
Registrato
19/2/08
Messaggi
20.659
Punti reazioni
255
Thu, Nov 1, 2012,
By Zacks Equity Research | Zacks – 8 hours ago

Pfizer Inc. (PFE) posted third quarter earnings of 53 cents per share, a penny above the Zacks Consensus Estimate but 12% below the year-ago earnings. Results were hit by the loss of exclusivity of certain products and the unfavorable impact of currency fluctuation. Revenues fell 16% to $13.9 billion, well below the Zacks Consensus Estimate of $14.6 billion.
Including one-time items, third quarter earnings from continuing operations fell 10% to 43 cents.
The Quarter in Detail
While foreign exchange cut third quarter revenues by $699 million or 4%, operational factors impacted revenues negatively by $1.9 billion or 12%.
International revenues declined 14% to $8.3 billion, mainly due to the unfavorable foreign exchange impact and the loss of Lipitor exclusivity. Meanwhile, US revenues declined 18% to $5.6 billion. US revenues were hit by the loss of exclusivity of Lipitor in November 2011.
Biopharmaceutical products delivered third quarter revenues of $12.1 billion, down 18%. While the Primary Care, Specialty Care, Emerging Markets and Oncology units in the Biopharmaceutical segment recorded a decline in sales, Established Products posted an increase in sales.
The Primary Care unit recorded a 39% decline in revenues, which came in at $3.6 billion. A change in reporting for Lipitor and other genericized products affected Primary Care revenues by about $2.4 billion or 40% year-over-year. Lyrica continued to perform well with sales coming in at $1,036 million, up 8%.
Specialty Care segment sales declined 10% to $3.4 billion. The Prevenar franchise put in a disappointing performance especially in the US and developed Europe as most patients have already been vaccinated. The segment was also impacted by about $260 million or 7% due to the genericization of Xalatan in developed Europe in January 2012 and Geodon in the US in March 2012.
Meanwhile, the launch of generic versions of branded Pfizer products and the inclusion of Lipitor revenues contributed to the 7% increase in Established Products revenues, which came in at $2.4 billion.
Lipitor was hit hard by the loss of exclusivity in the US. Despite making significant efforts to reduce the impact of generic competition, Pfizer saw Lipitor sales fall 87% to $192 million in the US. Generic competition increased as multiple players like Mylan (MYL) and Dr. Reddy’s Labs (RDY) launched their generic versions of Lipitor.
The third quarter saw revenues from Emerging Markets decline 2% to $2.4 billion. The Animal Health segment also recorded a 2% decline in revenues which came in at $1 billion.
Consumer Healthcare sales increased 2% to $780 million benefiting from the Ferrosan Consumer Health and Alacer Corp. acquisitions.
Selling, informational and administrative (SI&A) expenses fell 15% to $3.7 billion during the quarter. R&D expenses fell 4% to $1.9 billion. Pfizer made a $250 million payment to AstraZeneca (AZN) to obtain the exclusive global over-the-counter rights to Nexium. Pfizer remains committed to its cost-containment efforts and should realize cost savings due to workforce reductions, actions taken with the R&D portfolio, as well as savings from a smaller physical footprint.
Outlook Narrowed
Pfizer tightened some aspects of its 2012 outlook. The company now expects earnings of $2.14 - $2.17 per share on total revenues of $58 - $59 billion. Earlier, the company was expecting earnings of $2.12 - $2.22 per share on revenues of $58 - $60 billion. Pfizer now expects SI&A spend of $16.3 to $16.8 billion (old guidance: $16.3 to $17.3 billion) and R&D spend of $7.0 to $7.25 billion (old guidance: $6.75 to $7.25 billion). The Zacks Consensus Estimate currently stands at $2.20 per share on revenues of $59.4 billion.
Pfizer also announced a new $10 billion share buyback program which will be effective following the sale of the Nutrition business to Nestlé in the next few months. The new buyback program is in addition to the existing $4.1 billion buyback program.

Neutral on Pfizer
We currently have a Neutral recommendation on Pfizer, which carries a Zacks #3 Rank (short-term Hold rating). While near-term earnings will be driven by cost cutting efforts and share repurchases, longer-term growth will depend on the success of drug development. The company’s pipeline needs to deliver given the Lipitor loss of exclusivity and the upcoming loss of exclusivity on additional products in the next few years.

Pfizer Misses on Revs, Narrows View - Yahoo! Finance

.
 

Allegati

  • PFE advanced.png
    PFE advanced.png
    18,5 KB · Visite: 770
Ultima modifica: